AVANIR Pharmaceuticals Invites Investors to the Lazard Capital Markets Life Sciences Conference Webcast

AVANIR Pharmaceuticals (AMEX: AVN) announced today that
its presentation at the Lazard Capital Markets Annual Life Sciences
Conference in New York, NY, will be webcast live on November 30th,
2005, at 2:00 p.m. ET. An archived version of the webcast will be
available until December 30, 2005.
   Live and archived webcasts of the presentation will be accessible
through AVANIR's corporate website at http://www.avanir.com. To
access the webcasts, log on to AVANIR's site fifteen minutes prior to
the presentation to register and download any necessary audio
software.
   AVANIR Pharmaceuticals is focused on developing and
commercializing novel therapeutic products for the treatment of
chronic diseases. AVANIR's product candidates address therapeutic
markets that include central nervous system and cardiovascular
disorders, inflammation, and infectious disease. AVANIR recently
submitted to the FDA its New Drug Application for Neurodex(TM) for the
treatment of pseudobulbar affect. Additionally, AVANIR has initiated a
phase III clinical trial of Neurodex(TM) for the treatment of diabetic
neuropathic pain. AVANIR has active collaborations with two
international pharmaceutical companies: Novartis International
Pharmaceutical Ltd. for the treatment of inflammatory disease and
AstraZeneca UK Limited for the treatment of cardiovascular disease.
The Company's first commercialized product, Abreva(R), is marketed in
North America by GlaxoSmithKline Consumer Healthcare and is the
leading over-the-counter product for the treatment of cold sores.
Further information about AVANIR can be found at www.avanir.com.

   The information contained in this press release, including any
forward-looking statements contained herein, should be reviewed in
conjunction with the company's most recent Annual Report on Form 10-K
and other publicly available information regarding the company. Copies
of such information are available from the company upon request. Such
publicly available information sets forth many risks and uncertainties
related to the company's business and technology. Forward-looking
statements often contain such words like "estimate," "anticipate,"
"believe," "plan" or "expect." The company disclaims any intent or
obligation to update these forward-looking statements. Final review
decisions made by the FDA and other regulatory agencies concerning
clinical trial results are unpredictable and outside the influence
and/or control of the company.